logo
  

Misonix Up 10% On News Of Acquisition By Bioventus

Shares of minimally invasive therapeutic ultrasonic technologies and regenerative medicine provider Misonix, Inc. (MSON) are up more than 11% Friday morning at $26.45.

Thursday the company announced its decision to be bought by Bioventus Inc. (BVS) in a cash-and-stock transaction valued about $518 million.

As per the deal, Misonix stockholders can choose to receive either 1.6839 shares of Bioventus class A common stock or $28 in cash, for each Misonix share they hold.

The transaction is expected to close in the fourth quarter of 2021.

MSON touched a new high of $26.86 this morning.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
RELATED NEWS
Follow RTT